Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,268 | 0,292 | 13:02 | |
0,272 | 0,286 | 30.05. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
22.05. | IGC Pharma, Inc.: IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market | 414 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / May 22, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA... ► Artikel lesen | |
12.05. | IGC Pharma, Inc.: IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting | 203 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / May 12, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it presented its latest scientific poster, titled "Genetic Toxicity... ► Artikel lesen | |
IGC PHARMA Aktie jetzt für 0€ handeln | |||||
24.04. | IGC Pharma, Inc.: IGC Pharma Welcomes Strategic Investment from Advisors | 262 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / April 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company's recently appointed advisors entered into a Share... ► Artikel lesen | |
21.04. | IGC Pharma, Inc.: IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs | 274 | ACCESS Newswire | Industry Veterans Bring Deep Strategic Experience to Guide Alzheimer's Clinical Expansion and Commercial Strategy POTOMAC, MARYLAND / ACCESS Newswire / April 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC)... ► Artikel lesen | |
08.04. | IGC Pharma, Inc.: IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program | 300 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial with... ► Artikel lesen | |
01.04. | IGC Pharma, Inc.: IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health | 257 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation... ► Artikel lesen | |
26.03. | IGC Pharma, Inc.: IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances | 359 | ACCESS Newswire | - IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer's - POTOMAC, MD / ACCESS Newswire / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company")... ► Artikel lesen | |
20.03. | IGC Pharma, Inc.: IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences | 241 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the... ► Artikel lesen | |
17.03. | IGC Pharma, Inc.: IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida | 257 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / March 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of a new trial site at BayCare's St. Anthony's... ► Artikel lesen | |
12.03. | IGC Pharma, Inc.: IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25" | 181 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / March 12, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Ascendiant Capital Markets has issued a coverage report... ► Artikel lesen | |
10.03. | IGC Pharma, Inc.: IGC Pharma Announces Equity Analyst Update by Alliance Global Partners about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" | 230 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / March 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Alliance Global Partners (AGP) has issued an analyst update... ► Artikel lesen | |
06.03. | IGC Pharma, Inc. (IGC) Advances AI Model to Enhance Alzheimer's Diagnosis | 1 | Insider Monkey | ||
04.03. | IGC Pharma, Inc.: IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection | 266 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development... ► Artikel lesen | |
20.02. | IGC Pharma, Inc.: IGC Pharma Expands Holiby Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market | 139 | ACCESS Newswire | - New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function - POTOMAC, MD / ACCESS Newswire / February 20, 2025 / IGC Pharma, Inc. (NYSE American:IGC)... ► Artikel lesen | |
18.02. | IGC Pharma GAAP EPS of -$0.02, revenue of $257M | 1 | Seeking Alpha | ||
18.02. | IGC Pharma, Inc.: IGC Pharma Reports Third Quarter Fiscal 2025 Results | 312 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended... ► Artikel lesen | |
11.02. | IGC Pharma, Inc.: IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby | 278 | ACCESS Newswire | - Product Launch Leverages IGC's State-Of-The-Art Manufacturing Facility To Support Revenue-Generating Brand for Immunity & Energy - POTOMAC, MD / ACCESS Newswire / February 11, 2025 / IGC Pharma, Inc.... ► Artikel lesen | |
28.01. | IGC Pharma, Inc.: IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease | 323 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / January 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is proud to announce its selection as one of the top 15 finalists in the PREPARE... ► Artikel lesen | |
21.01. | IGC Pharma, Inc.: IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor | 532 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of... ► Artikel lesen | |
13.01. | IGC Pharma, Inc.: IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets | 291 | ACCESS Newswire | POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 24,735 | +0,04 % | Erfolg für Bayer | Die Europäische Arzneimittel-Agentur EMA empfiehlt eine Zulassungserweiterung für eine höher dosierte Version von Bayers Augenmedikament Eylea. Durch die Verlängerung der Behandlungsintervalle auf bis... ► Artikel lesen | |
NOVO NORDISK | 62,90 | +0,06 % | Novo Nordisk-Aktie: Düstere Aussichten | Die Aktie von Novo Nordisk hat in den vergangenen Monaten eine extrem schwache Performance abgeliefert. Doch auch mit Blick nach vorn sieht es nicht besser aus, zumindest wenn man einer aktuellen Studie... ► Artikel lesen | |
PFIZER | 20,660 | +0,02 % | BERENBERG stuft PFIZER INC auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Pfizer von 28 auf 25 US-Dollar gesenkt und die Einstufung auf "Hold" belassen. Da neue Medikamente die Einbußen durch das Auslaufen... ► Artikel lesen | |
NOVARTIS | 100,72 | -1,18 % | EQS-News: Novartis Pharma GmbH: Chancen und Perspektiven bei der Therapie des Prostatakarzinoms - Diskussion mit Expert*innen aus Medizin, Patientenvertretung und Industrie | EQS-News: Novartis Pharma GmbH
/ Schlagwort(e): Sonstiges
Chancen und Perspektiven bei der Therapie des Prostatakarzinoms - Diskussion mit Expert*innen aus Medizin, Patientenvertretung... ► Artikel lesen | |
MERCK KGAA | 115,50 | +0,22 % | Bayer, Evonik, Merck investieren Milliarden - aber bleibt die Forschung in Deutschland? | Rekordinvestitionen, doch der Druck steigt: Die deutsche Chemie- und Pharmaindustrie steckt so viele Milliarden in Forschung wie nie zuvor. Doch Asien zieht davon. Warum der Standort Deutschland ins... ► Artikel lesen | |
GILEAD SCIENCES | 97,19 | +0,32 % | Gilead Sciences Commemorated the Opening of the Bay Area Young Survivors Breast Cancer Memorial Garden | NORTHAMPTON, MA / ACCESS Newswire / May 30, 2025 / Gilead Sciences:We recently commemorated the opening of the Bay Area Young Survivors Breast Cancer Memorial Garden in San Francisco's Golden Gate Park.... ► Artikel lesen | |
AURORA CANNABIS | 4,690 | +0,54 % | Unglaubliche Prognose für Montag setzt Aurora Cannabis Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
SANOFI | 87,48 | -4,95 % | Minimale Kursveränderung bei Sanofi SA-Aktie (92,33 €) | Der Kurs der dem Anteilsschein von Sanofi SA kommt kaum von der Stelle. Der jüngste Kurs betrug 92,33 Euro. Die Wertschätzung der Börsenteilnehmer für die Aktie von Sanofi SA hat sich heute kaum verändert.... ► Artikel lesen | |
ABBVIE | 163,60 | -0,12 % | AbbVie flies the W against cancer with Chicago Cubs partnership, ASCO corporate campaign | ||
CANOPY GROWTH | 1,170 | +0,86 % | Nach zuletzt starken Gewinnen: Erwartung verfehlt: Crasht jetzt die Aktie von Canopy Growth? | © Foto: Dall-EDer kanadische Cannabiskonzern Canopy Growth hat mit seinen am Freitagmittag vorgelegten Quartalszahlen die Erwartungen der Analysten nicht erfüllen können.In den vergangenen Wochen ist... ► Artikel lesen | |
ELI LILLY | 649,20 | +1,95 % | Prognose dramatisch gekürzt: Schlechte Nachrichten für Anleger von Eli Lilly und Novo Nordisk? | © Foto: manaemedia - picture allianceEli Lilly und Novo Nordisk, die aktuellen Stars der Pharmabranche, könnten laut einer Studie von Goldman Sachs vor schwächeren Geschäften als erwartet stehen.Die... ► Artikel lesen | |
MERCK & CO | 67,90 | +0,30 % | Merck, Daiichi Sankyo Say Biologics License Application Withdrawn For Patritumab Deruxtecan | KENILWORTH (NJ) (dpa-AFX) - The Biologics License Application (BLA) seeking accelerated approval of patritumab deruxtecan, co-developed by Merck & Co Inc. (MRK) and Daiichi Sankyo Company, Limited... ► Artikel lesen | |
ASTRAZENECA | 127,65 | +3,03 % | Ihre wichtigsten Termine: Alle Augen auf Nvidia, Salesforce, HP, Meta, ExxonMobil, Astrazeneca, Teamviewer | © Foto: Andrea Warnecke/dpa-tmn/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
TILRAY BRANDS | 0,379 | -0,94 % | Unglaubliche Prognose für Montag setzt Tilray Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! |